Insmed Incorporated (NASDAQ:INSM) Insider Martina M.D. Flammer Sells 37,828 Shares of Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 37,828 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $78.61, for a total value of $2,973,659.08. Following the completion of the transaction, the insider now owns 100,165 shares of the company’s stock, valued at approximately $7,873,970.65. This trade represents a 27.41 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Martina M.D. Flammer also recently made the following trade(s):

• On Thursday, February 6th, Martina M.D. Flammer sold 33,055 shares of Insmed stock. The stock was sold at an average price of $80.90, for a total transaction of $2,674,149.50.
• On Tuesday, January 14th, Martina M.D. Flammer sold 1,384 shares of Insmed stock. The stock was sold at an average price of $68.72, for a total transaction of $95,108.48.
• On Friday, January 10th, Martina M.D. Flammer sold 6,172 shares of Insmed stock. The stock was sold at an average price of $63.64, for a total transaction of $392,786.08.
• On Tuesday, January 7th, Martina M.D. Flammer sold 3,344 shares of Insmed stock. The shares were sold at an average price of $65.91, for a total transaction of $220,403.04.

Insmed Trading Down 0.4 %

NASDAQ:INSM opened at $79.60 on Thursday. The company has a 50 day simple moving average of $73.15 and a two-hundred day simple moving average of $73.16. The company has a market cap of $14.24 billion, a PE ratio of -14.34 and a beta of 1.11. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $82.04.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on INSM shares. JPMorgan Chase & Co. raised their price objective on Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Friday, February 7th. Stifel Nicolaus raised their price target on Insmed from $88.00 to $97.00 and gave the company a “buy” rating in a report on Tuesday. Truist Financial reaffirmed a “buy” rating and issued a $105.00 price target (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. HC Wainwright reissued a “buy” rating and set a $90.00 price objective on shares of Insmed in a research report on Friday, November 1st. Finally, Guggenheim lifted their target price on shares of Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a report on Friday, February 7th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $85.60.

Hedge Funds Weigh In On Insmed

Several institutional investors have recently made changes to their positions in INSM. Geode Capital Management LLC boosted its stake in shares of Insmed by 7.2% during the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company’s stock worth $282,243,000 after acquiring an additional 273,759 shares during the last quarter. National Bank of Canada FI raised its holdings in Insmed by 9.7% in the 4th quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company’s stock worth $115,000 after purchasing an additional 147 shares during the period. HighPoint Advisor Group LLC purchased a new position in Insmed during the fourth quarter valued at $248,000. Clearbridge Investments LLC grew its holdings in Insmed by 3.9% during the fourth quarter. Clearbridge Investments LLC now owns 1,878,450 shares of the biopharmaceutical company’s stock valued at $129,688,000 after purchasing an additional 69,683 shares during the period. Finally, Intrust Bank NA increased its position in Insmed by 12.1% in the fourth quarter. Intrust Bank NA now owns 5,566 shares of the biopharmaceutical company’s stock worth $384,000 after buying an additional 600 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.